Saturday 17 October 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 188.0%, free cash flow fell 78.3% and total debt fell 11.5%, each against the same quarter a year earlier.
32.10
2.16
−6.30%
Follow DFTX
Definium Therapeutics, Inc. (DFTX) P/E ratio
Definium Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| COGT Cogent Biosciences, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. compare | n/m |
| SRRK Scholar Rock Holding Corporation compare | n/m |
| DFTX Definium Therapeutics, Inc. | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)